Spanish biotech gets backing from investors: 4 companies raised more than €3M in May
09/06/2017
Diego Gutiérrez
Spanish biotech gets backing from investors: 4 companies raised more than €3M in May
Anaconda Biomed, Vivacell, Devicare and Apta Targets are the Spanish biotechs that have secured investor backing in May with the aim of bringing their products to market.
Spanish biotech gets backing from investors: 4 companies have raised more than €3M in May
Anaconda Biomed -€15M

Anaconda Biomed, a Catalan company that develops devices for the treatment of stroke, has received a €15M round.

With this round, the company aims to develop Anaconda Biomed's ANCD Brain device, obtain regulatory approval in Europe and introduce the product to the European market. The funds will also allow the company to initiate FDA approval procedures in the US.

The round was led by Ysios Capital, one of the most active biotech investors in Spain. Other investors include Banco Sabadell, as the first operation in the biomedical sector, as well as the specialised international funds Innogest Capital and Omega Funds.

Anaconda Biomed, which was founded in 2015, had already received a small round in 2016, but the round it has just closed will be the final one to bring its devices to market.

Vivacell-€3.2M

Vivacell is a company located in the Cordova Science Park. The company is a world pioneer in research and development of drugs that target the endocannabinoid system and holds six international patents on new chemical entities designed to act on the endocannabinoid system.

The company has recently received €3.2 million from the Canadian company Emerald Health, which had previously invested in the company.

The proceeds will be used to support VivaCell's ongoing research and development programmes for cannabis-derived medicines.

Devicare €3M

Devicare, as we mentioned in a previous post, develops innovative medical devices for the home care of chronic patients. The company has just closed a €3M round to consolidate the launch and clinical studies of the first two product lines in the Spanish market: Lit-Control® for the prevention and self-management of recurrent urinary diseases and Tao-Control® for the self-management of patients taking oral anticoagulants (Sintrom®, Aldocumar®, etc.).

Apta Targets €2.7M

"La Caixa, through its venture capital firm Caixa Capital Risc, and Inveready have invested €2.7M in biopharmaceutical company AptaTargets to complete the pre-clinical phase and enter Phase I and II clinical trials of its first drug candidate (ApTOLL) for the acute phase treatment of ischaemic stroke.

AptaTargets is a biopharmaceutical company that started its activity in 2016 and is dedicated to the development of innovative molecules based on aptamer technology. The molecules it develops are neuroprotectants and immunomodulators, from preclinical phases to complete proof of concept in the clinic.

Other posts that may interest you

 

If you are looking for investors, you want to buy or selling a companyplease contact us. Abra-Invest has a team of experts in each area at your disposal. Call +34 946424142 or fill in the contact form.

Lastest news

Latest transactions in the Cybersecurity sector

El sector de la ciberseguridad ha sido testigo de una importante oleada de adquisiciones estratégicas en los últimos meses, a medida que las empresas tratan de ampliar sus capacidades y hacer frente a la creciente demanda de una sólida protección digital. Cinco...

Latest transactions in the Consumer Software sector

El sector del Consumer software ha experimentado recientemente una dinámica oleada de adquisiciones que pone de relieve su evolución hacia la mejora de la participación de los usuarios y la ampliación de los servicios digitales. Entre las operaciones más destacadas...

Latest transactions in the Industrial Tech sector

El sector de la tecnología industrial ha sido testigo de una oleada de transacciones estratégicas en los últimos meses, señal de una rápida evolución y expansión. Entre las operaciones más destacadas, Bosch Energy and Building Solutions adquirió DMS Ettlingen para...

Do you want to sell or buy a company?

We are experts in M&A transactions in the technology sector.

Subscribe to our newsletter

Request for information

If you want to buy or sell a company, or need more information about our services, do not hesitate to contact us through the form.

Or if you prefer, call us at:

+34 946 42 41 42